VITamin D and OmegA-3 TriaL (VITAL) bone health ancillary study: clinical factors associated with trabecular bone score in women and men
We investigated the association of clinical variables with TBS at baseline in the bone health sub-cohort of the VITamin D and OmegA-3 TriaL (VITAL). Lower TBS was associated with female sex, aging, BMI ≥ 25 kg/m2, SSRI use, high alcohol intake, and presence of diabetes; there was a trend towards significance between lower TBS and history of fragility fractures.
We investigated whether TBS differs by sex, race, body mass index (BMI), and other clinical variables.
The VITamin D and OmegA-3 TriaL (VITAL) is determining effects of vitamin D3 and/or omega-3 fatty acid (FA) supplements in reducing risks of cancer and cardiovascular disease. In the VITAL: Effects on Bone Structure/Architecture ancillary study, effects of these interventions on bone will be investigated. Here, we examine the associations of clinical risk factors with TBS assessments at baseline in the bone health sub-cohort, comprised of 672 participants (369 men and 303 women), mean (± SD) age 63.5 ± 6.0 years; BMI ≤ 37 kg/m2, no bisphosphonates within 2 years or other bone active medications within 1 year.
TBS was greater in men than women (1.311 vs. 1.278, P < 0.001) and lower with elevated BMIs (P < 0.001), higher age (P = 0.004), diabetes (P = 0.008), SSRI use (P = 0.044), and high alcohol intake (P = 0.009). There was a trend for history of fragility fractures (P = 0.072), and lower TBS. TBS did not vary when analyzed by race, smoking, history of falls, and multivitamin or caffeine use.
Lower TBS was associated with female sex, aging, BMI ≥ 25 kg/m2, SSRI use, alcohol use, and presence of diabetes; there was a trend between lower TBS and history of fragility fractures. TBS may be useful clinically to assess structural changes that may be associated with fractures among patients who are overweight or obese, those on SSRIs, or with diabetes. Ongoing follow-up studies will clarify the effects of supplemental vitamin D3 and/or FA’s on TBS and other bone health measures.
KeywordsFracture Osteoporosis SSRI TBS Trabecular bone score
Members of the VITAL Data and Safety Monitoring Board include Lawrence S. Cohen, Theodore Colton, Mark A. Espeland, I. Craig Henderson, Alice H. Lichtenstein, Rebecca A. Silliman, and Nanette K. Wenger (chair), and Josephine Boyington, Cindy D. Davis, Rebecca B. Costello, Gabriela Riscuta, Harold Seifried, Lawrence Fine, and Peter Greenwald (ex-officio members). We would also like to acknowledge Vadim Bubes and Gregory Kotler, the data analysts for this project. We would also like to acknowledge the contribution of the Steve Cobb Junior Faculty Education Fund. In addition, we would like to acknowledge Andrea Alvarez, a summer research student from Winsor High School, for her contributions to this research.
Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers R01AR59775 (LeBoff, M.S., PI) and R01AR060574 (LeBoff, M.S., PI), respectively. The parent VITAL trial is supported by grant U01CA138962 (Manson, J. and Buring, J, PIs). Support for this research was also provided from the Harvard Catalyst Clinical and Translational Science Center (CTSC) (NIH Award UL1 TR001102) and the Steve Cobb Junior Faculty and Fellow Education Fund. Pharmavite LLC of Northridge, California (vitamin D) and Pronova BioPharma (BASF) of Norway (Omacor® fish oil) donated the study agents, matching placebos, and packaging in the form of calendar packs.
Compliance with ethical standards
Conflicts of interest
- 2.Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526. https://doi.org/10.1002/jbmr.2269 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14(3):302–312. https://doi.org/10.1016/j.jocd.2011.05.005 CrossRefPubMedGoogle Scholar
- 5.Rabier B, Heraud A, Grand-Lenoir C, Winzenrieth R, Hans D (2010) A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): analysing the odds of vertebral fracture. Bone 46(1):176–181. https://doi.org/10.1016/j.bone.2009.06.032 CrossRefPubMedGoogle Scholar
- 10.McCloskey EV, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJ, Fujita Y, Gluer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren O, Lorentzon M, Mellstrom D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31(5):940–948. https://doi.org/10.1002/jbmr.2734 CrossRefPubMedGoogle Scholar
- 14.Romagnoli E, Cipriani C, Nofroni I, Castro C, Angelozzi M, Scarpiello A, Pepe J, Diacinti D, Piemonte S, Carnevale V, Minisola S (2013) “Trabecular bone score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53(1):154–159. https://doi.org/10.1016/j.bone.2012.11.041 CrossRefPubMedGoogle Scholar
- 17.LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE (2015) VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials 41C:259–268. https://doi.org/10.1016/j.cct.2015.01.007 CrossRefGoogle Scholar
- 18.Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, Liu S, Looker AC, Wallace TC, Wang DD (2016) Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 27(1):367–376. https://doi.org/10.1007/s00198-015-3386-5 CrossRefPubMedGoogle Scholar
- 19.Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE (2011) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159–171. https://doi.org/10.1016/j.cct.2011.09.009 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Donlon CM, LeBoff MS, Chou SH, Cook NR, Copeland T, Buring JE, Bubes V, Kotler G, Manson JE (2018) Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture. Contemp Clin Trials 67:56–67. https://doi.org/10.1016/j.cct.2018.02.003 CrossRefPubMedGoogle Scholar
- 23.Looker AC, Sarafrazi Isfahani N, Fan B, Shepherd JA (2016) Trabecular bone scores and lumbar spine bone mineral density of US adults: comparison of relationships with demographic and body size variables. Osteoporos Int 27(8):2467–2475. https://doi.org/10.1007/s00198-016-3550-6 CrossRefPubMedGoogle Scholar
- 26.Shin YH, Gong HS, Lee KJ, Baek GH (2017) Older age and higher body mass index are associated with a more degraded trabecular bone score compared to bone mineral density. J Clin Densitom. https://doi.org/10.1016/j.jocd.2017.06.006
- 27.Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167(12):1246–1251. https://doi.org/10.1001/archinte.167.12.1246 CrossRefPubMedGoogle Scholar
- 28.Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA (2008) Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 23(2):84–87. https://doi.org/10.1097/YIC.0b013e3282f2b3bb CrossRefPubMedGoogle Scholar
- 37.Beck TJ, Petit MA, Wu G, LeBoff MS, Cauley JA, Chen Z (2009) Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res 24(8):1369–1379. https://doi.org/10.1359/jbmr.090307 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Luckey MM, Meier DE, Mandeli JP, DaCosta MC, Hubbard ML, Goldsmith SJ (1989) Radial and vertebral bone density in white and black women: evidence for racial differences in premenopausal bone homeostasis. J Clin Endocrinol Metab 69(4):762–770. https://doi.org/10.1210/jcem-69-4-762 CrossRefPubMedGoogle Scholar
- 41.Putman MS, Yu EW, Lee H, Neer RM, Schindler E, Taylor AP, Cheston E, Bouxsein ML, Finkelstein JS (2013) Differences in skeletal microarchitecture and strength in African-American and white women. J Bone Miner Res 28(10):2177–2185. https://doi.org/10.1002/jbmr.1953 CrossRefPubMedPubMedCentralGoogle Scholar